ChromaVision Medical Systems
This article was originally published in The Gray Sheet
Private placement of 1.78 mil. common stock shares at $11.25 each with selected institutional and other accredited investors raises $20 mil. The San Juan Capistrano, California firm rolled out its ACIS automated cellular imaging system in July following FDA clearance (1"The Gray Sheet" Aug. 2, In Brief). Proceeds will be used to continue the firm's transition from R&D to "active promotion and selling" of the ACIS system, the company reports. Prudential Vector Healthcare Group was placement agent for the financing
You may also be interested in...
Rolls out its ACIS automated cellular imaging system following FDA clearance for use with any immunohistochemistry (IHC) staining test that has undergone company validation, ChromaVision announces July 29. The system will be capable of processing IHC slides for micrometastases detection immediately, ChromaVision notes. Analysis of HER-2/neu tests will be added in the next 30 days, followed by cytomegalovirus, estrogen and progesterone tests in the fourth quarter. ChromaVision plans to offer the instrument at no cost and charge institutions for each test result, with prices ranging from roughly $30 for infectious disease tests to $150 for some complex cancer tests. In clinical studies, pathologists reversed 44% of initially negative diagnoses when using the instrument, which provides a 300% increase in sensitivity over manual methods, ChromaVision claims
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.